MaaT Pharma

MaaT Pharma is a late-stage clinical biotechnology company that was founded in 2014 in Lyon, France. The company is focused on developing microbiome-based therapies to improve outcomes for cancer patients.

MaaT Pharma's approach is to use the gut microbiome to modulate the immune system. The company has developed a proprietary platform, called MaaT Microbiome Restoration Biotherapeutics (MMRB), to create standardized, high-diversity microbiome drug candidates. This platform utilizes pooling and co-cultivation technologies to ensure the consistency and quality of its products.

The company's lead product candidate, MaaT013, is in late-stage clinical development for the treatment of acute Graft-versus-Host Disease (aGvHD), a life-threatening complication of allogeneic hematopoietic stem cell transplantation. MaaT Pharma is also developing MaaT033, a second-generation product candidate, for the prevention of complications after allogeneic hematopoietic stem cell transplantation.

MaaT Pharma's business model is focused on the development and commercialization of its microbiome-based therapies. The company generates revenue through a combination of research and development collaborations, licensing agreements, and product sales. MaaT Pharma is publicly traded on the Euronext Paris stock exchange under the ticker symbol MAAT since 2021.

Keywords: microbiome, oncology, immunotherapy, biotechnology, clinical-stage, gut-health, cancer-therapies, graft-versus-host-disease, biotherapeutics, drug-development